Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | See Remarks | February 14, 2018 | February 16, 2018 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | PRESIDENT AND COO | June 05, 2026 | June 08, 2026 |
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Global Blood Therapeutics, Inc.
Report date February 14, 2018 · Filed February 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,627 |
Reported balance
After 2018-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-14 · Exercise / conversion · Acquired 1,600 · Balance 9,627 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2: Includes 661 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 549 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3. |
| Common StockSEC Table I · non-derivative | Direct | 8,833 |
Reported balance
After 2018-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-02-14 · Tax withholding · Disposed 794 · Balance 8,833 F3: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,600 |
Reported balance
After 2018-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-14 · Exercise / conversion · Disposed 1,600 · Balance 5,600 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F4: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2: Includes 661 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 549 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3.
F3: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs.
F4: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Mirum Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,260 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 16,988 · Balance 57,260 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2031-01-06 | Direct | 48,012 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 16,988 · Balance 48,012 F1: The stock option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option is fully vested.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
1 source rowRow 1 · 2024-01-26 · Other · Disposed 8,796 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 42,596 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Aug 19, 2022 17:35 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0000899243-22-029314 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's common stock, which will vest in full on June 1, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:24 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,169 | $13.57 | $15,858.65 |
DisclosureSEC source: 0001209191-22-028728 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,400 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,169 shares by the Reporting Person on May 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:55 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001209191-22-002431 · doc4.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-05 F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:55 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002431 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,231 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 21:21 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 958 | $13.52 | $12,947.37 |
DisclosureSEC source: 0001209191-21-064450 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,231 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 958 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,364 | $19.26 | $26,264.50 |
DisclosureSEC source: 0001209191-21-058605 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,273 F2 · shares: Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021. Read SEC document |
| September 29, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058605 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,637 F1 · shares: The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,062 shares on September 29, 2021 and 4,063 shares on June 30, 2023. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:45 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,006 | $14.62 | $14,707.72 |
DisclosureSEC source: 0001209191-21-032160 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,512 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,006 shares by the Reporting Person on May 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 17:07 UTC | Rain Oncology Inc. RAIN · Entity 94695 | ConversionSeries A Preferred Stock · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017114 · doc4.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 8,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 17:07 UTC | Rain Oncology Inc. RAIN · Entity 94695 | ConversionCommon Stock | 8,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017114 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:36 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001209191-21-003030 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:16 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 861 | $15.27 | $13,144.03 |
DisclosureSEC source: 0001209191-20-058052 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,506 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 861 shares by the Reporting Person on November 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 23:38 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-026418 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: 1/4th of the shares vest one year after April 28, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of April 28, 2020. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 19:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-004445 · doc4.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 19:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 794 | $62.30 | $49,466.20 |
DisclosureSEC source: 0000899243-18-004445 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 19:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-004445 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2 · balance_after: Includes 661 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 549 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · derivative · entry 9 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F8 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 26,500 | $0.00 Strike: $59.60 | $0.00 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · derivative · entry 8 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2028-01-31 F7 · derivative.exercise_date: The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · derivative · entry 7 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On January 17, 2017, the Reporting Person was granted 24,000 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: On January 17, 2017, the Reporting Person was granted 24,000 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 812 | $57.30 | $46,527.60 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · nonDerivative · entry 5 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,817 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,038 | $59.60 | $61,864.80 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · nonDerivative · entry 4 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,629 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · nonDerivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · derivative · entry 6 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 554 | $57.90 | $32,076.60 |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:17 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002765 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002114 · doc4.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 560 | $58.15 | $32,564.00 |
DisclosureSEC source: 0000899243-18-002114 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,621 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002114 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:09 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000899243-18-002043 · doc4.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 30,000 shares Expires 2025-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on November 17, 2015, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:09 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 30,000 | $60.00 | $1,800,000.00 |
DisclosureSEC source: 0000899243-18-002043 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,581 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:09 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 30,000 | $1.61 | $48,300.00 |
DisclosureSEC source: 0000899243-18-002043 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001363 · doc4.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 703 | $52.10 | $36,626.30 |
DisclosureSEC source: 0000899243-18-001363 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,581 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-001363 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 21:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000899243-18-000952 · doc4.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 15,000 shares Expires 2025-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on November 17, 2015, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 21:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 15,000 | $50.00 | $750,000.00 |
DisclosureSEC source: 0000899243-18-000952 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 21:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 15,000 | $1.61 | $24,150.00 |
DisclosureSEC source: 0000899243-18-000952 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 20:15 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 12,500 | $35.00 | $437,500.00 |
DisclosureSEC source: 0000899243-17-025039 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:37 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,410 | $30.00 | $72,300.00 |
DisclosureSEC source: 0000899243-17-021480 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:47 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020283 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F2 · derivative.expiration_date: The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:36 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019708 · doc4.xml · derivative · entry 4 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On January 17, 2017, the Reporting Person was granted 24,000 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On January 17, 2017, the Reporting Person was granted 24,000 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:36 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,128 | $25.10 | $28,312.80 |
DisclosureSEC source: 0000899243-17-019708 · doc4.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,094 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:36 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-019708 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| July 31, 2017 Filed Feb 14, 2018 19:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 661 | $13.69 | $9,049.09 |
DisclosureSEC source: 0000899243-18-003992 · doc5.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2017 Filed Feb 14, 2017 18:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 812 | $13.73 | $11,148.76 |
DisclosureSEC source: 0000899243-17-004064 · doc5.xml · nonDerivative · entry 3 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 F2 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0000899243-17-001587 · doc4.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-01-16 F2 · derivative.exercise_date: The shares underlying the option vest in equal quarterly installments over 16 quarters from January 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001587 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 18:41 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-16-030598 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2025-04-08 F1 · balance_after: On April 9, 2015, the reporting person was granted an option to purchase 30,000 shares of Common Stock under the issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 7,500 of the shares underlying such option. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 19:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.89 | $0.00 |
DisclosureSEC source: 0000899243-16-028831 · doc4.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments, with the first installment on December 8, 2016, subject to the recipient's continued service with the Issuer. Read SEC document |
| July 31, 2016 Filed Feb 14, 2017 18:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 1,185 | $15.20 | $18,012.00 |
DisclosureSEC source: 0000899243-17-004064 · doc5.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,410 F2 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.